Pulmonary Arterial Hypertension and TGF-β Superfamily Signaling: Focus on Sotatercept
- 18 September 2024
- journal article
- research article
- Published by Springer Nature in BioDrugs
- Vol. 38 (6) , 743-753
Abstract
Pulmonary arterial hypertension (PAH) is a rare and progressive disease that continues to remain highly morbid despite multiple advances in medical therapies. There remains a persistent and desperate need to identify novel methods of treating and, ideally, reversing the pathologic vasculopathy that results in PAH development and progression. Sotatercept is a first-in-class fusion protein that is believed to primarily inhibit activin signaling resulting in decreased cell proliferation and differentiation, though the exact mechanism remains uncertain. Here, we review the currently available PAH therapies, data highlighting the importance of transforming growth factor-β (TGF-β) superfamily signaling in the development of PAH, and the published and on-going clinical trials evaluating sotatercept in the treatment of PAH. We will also discuss preclinical data supporting the potential use of the fusion protein KER-012 in the inhibition of aberrant TGF-β superfamily signaling to ameliorate the obstructive vasculopathy of PAH.Keywords
This publication has 53 references indexed in Scilit:
- Long-Term Effects of Sotatercept on Right Ventricular FunctionJACC: Heart Failure, 2023
- Homozygous GDF2 nonsense mutations result in a loss of circulating BMP9 and BMP10 and are associated with either PAH or an “HHT‐like” syndrome in childrenMolecular Genetics & Genomic Medicine, 2021
- Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cellsAngiogenesis, 2020
- The role of genetics in pulmonary arterial hypertensionThe Journal of Pathology, 2016
- Bosentan reverses the hypoxia-induced downregulation of the bone morphogenetic protein signaling in pulmonary artery smooth muscle cellsLife Sciences, 2016
- Incidence and prevalence of pulmonary arterial hypertension in GermanyInternational Journal of Cardiology, 2016
- Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertensionNature Medicine, 2015
- Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal womenThe Journal of Clinical Pharmacology, 2013
- BMP9 Mutations Cause a Vascular-Anomaly Syndrome with Phenotypic Overlap with Hereditary Hemorrhagic TelangiectasiaThe American Journal of Human Genetics, 2013
- TGFβ signalling in contextNature Reviews Molecular Cell Biology, 2012